[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(10/8, THU) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)

 노벨화학상, ‘거울상 이성질체’ 규명 2人 수상
[https://www.biospectator.com/news/view/30030](https://www.biospectator.com/news/view/30030)

 티카로스, ‘MUC-1 CAR-T’ 고형암1상 식약처 “IND 제출”
[https://www.biospectator.com/news/view/30025](https://www.biospectator.com/news/view/30025)

 애브비, 'CD20xCD3' 병용 DLBCL 1차 3상 "PFS 51%↑" 
[https://www.biospectator.com/news/view/30015](https://www.biospectator.com/news/view/30015)

 네덜란드 법원, 유럽 8개국서 '키트루다SC' 판매금지 명령
[https://www.biospectator.com/news/view/30031](https://www.biospectator.com/news/view/30031)

 에스티팜, CPHI 부스 참가..글로벌 CDMO 확대 모색 
[https://www.biospectator.com/news/view/30036](https://www.biospectator.com/news/view/30036)

 9월 비상장 바이오투자, 4곳 315억.."초기투자 몰려"
[https://www.biospectator.com/news/view/30011](https://www.biospectator.com/news/view/30011)

 'FcRn 경쟁' 누빅, 'Fc절편' CIDP 2상 "5개월만에 중단"
[https://www.biospectator.com/news/view/30018](https://www.biospectator.com/news/view/30018)

 시오노기, 인트라바이오 20억弗 인수.."희귀질환 강화"
[https://www.biospectator.com/news/view/30017](https://www.biospectator.com/news/view/30017)

 애스톤, 'mRNA 암백신' 스케일업팁스 R&D "사업 선정"
[https://www.biospectator.com/news/view/30038](https://www.biospectator.com/news/view/30038)

 '다우드나' 카리부, '동종 CAR-T' 중단.."전략적 모색"
[https://www.biospectator.com/news/view/30033](https://www.biospectator.com/news/view/30033)

 마더스제약, 코스닥 상장예비심사 "통과"
[https://www.biospectator.com/news/view/30039](https://www.biospectator.com/news/view/30039)

‘CNS 신약’ 아델, 코스닥 상장예비심사 "통과"
[https://www.biospectator.com/news/view/30040](https://www.biospectator.com/news/view/30040)

[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(10/8, THU) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)